Officials Commend Partnership Among Yale Pathology, Yale School of Public Health and State Health Department to Expand SalivaDirect™ Testing at 2 New Haven Sites
Officials from the Yale Department of Pathology, the Yale School of Public Health and the Yale School of Medicine, along with Congresswoman Rosa DeLauro and Lt. Gov. Susan Bysiewicz, held a press conference Jan. 27 in New Haven’s Long Wharf to mark the opening of two free COVID-19 testing sites.
Yale-led Study Finds the Affordable Care Act Prevented Thousands of Colorectal Cancer Cases and Deaths
Can removing out-of-pocket costs for screening save lives? Screening for cancer and other diseases can identify the disease in its earlier stages of development and has been found to be highly effective in preventing the onset of illness.
National Cancer Center Partnership Expected to Advance Cancer Research at YSPH, Yale
A new partnership with the National Cancer Center of China will provide opportunities for collaborative research, clinical trials and workforce training at the Yale School of Public Health, Yale Cancer Center and Yale Institute for Global Health.
Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Novel YSPH Framework Helps Identify Genes Associated with Disease
A powerful analytical tool, known as UTMOST, developed by Hongyu Zhao, Ph.D., the Ira V. Hiscock Professor of Biostatistics at the Yale School of Public Health, and colleagues could allow researchers to design therapeutic drugs that more effectively combat disease.
Would Routine Genomic Testing For Cancer And Heart Risk Make Economic Sense?
If all adults were to have their genes sequenced during their annual physicals this year, the vast majority of us would not learn anything that would change our medical routines going forward. But an estimated 1% of Americans—at least 3 million people—would find genetic abnormalities that greatly raise their risk of cancer or heart disease. And that, says Yale School of Medicine genetics expert Michael Murray, would make all of that testing worth it, not only to those individuals, but to society as a whole. Even if each person had just 10 genes tested, the benefits would outweigh the costs, argues Murray, who wrote an article published today in the journal Annals of Internal Medicine that urges health systems to embrace routine genomic testing. That’s because such testing would reveal “actionable” gene mutations—well-known risks for diseases that can be avoided with specific screening or prevention methods.Source: Forbes
New Centers to Advance Implementation and Prevention Sciences
Two new centers at the School of Medicine and the School of Public Health will promote the adoption of research findings into clinical practice and develop and assess sustainable, cost-effective interventions to improve public health domestically and around the world.
Proposed legislation would subject e-cigarettes to age verification law
New legislation proposed June 5 by Congresswoman Rosa DeLauro, D-Conn., would require Internet and mail order sellers of electronic cigarettes to verify a person’s age and identity before they deliver their products to a buyer’s door.
Breast cancer care in U.S. territories lags behind care in states
Older women residing in the U.S territories are less likely to receive recommended or timely care for breast cancer compared with similar women residing in the continental United States, according to Yale researchers. Their findings were published in the March issue of Health Affairs.
Affordable Care Act lowered uninsured rate for cancer survivors
The percentage of cancer survivors without health insurance decreased substantially after implementation of the Affordable Care Act (ACA), reports a study in the March issue of Medical Care, published by Wolters Kluwer. Cancer survivors eligible for Medicaid expansion under the ACA had the greatest decrease in uninsured rate, according to the new research by Amy J. Davidoff, PhD, of Yale School of Public Health, New Haven, Conn., and colleagues. They write, "ACA implementation was associated with large coverage gains in targeted expansion groups, including cancer survivors, but additional progress is needed."Source: Eurekaalert
Solomon Center to Host Conference on Policy, Politics and Law of Cancer
The Solomon Center for Health Law and Policy at Yale Law School—in collaboration with Smilow Cancer Hospital and Yale Cancer Center—will host a major interdisciplinary conference addressing topics at the cutting edge of cancer policy. Titled “The Policy, Politics and Law of Cancer,” the conference will be held in New Haven on February 8-9th, 2018. his event brings together leading figures in the worlds of cancer care, research, regulation, and policymaking to assess the current state of cancer policy and discuss ways in which law can influence its development. No event of comparable scale has been held in Connecticut—and the conference breaks new ground substantively, both within Connecticut and beyond, according to the organizers.Source: Yale Law
Opportunities to vaccinate young women against HPV missed at alarming rate
en aged 18-26 who were eligible to receive Human Papilloma Virus (HPV) vaccine have missed at least one opportunity to receive the vaccine during a visit to an obstetrics and gynecology clinic, Yale researchers report. This study also confirms previous research showing racial disparities in vaccination for HPV: Women who identify as black are 61% more likely have had a missed opportunity than women who identify as white. These findings are published in the American Journal of Obstetrics and Gynecology. HPV is a well-known cause of pre-cancerous cervical lesions, which, if untreated, could develop into cervical cancer. Immunization against HPV has been shown to be safe and effective in preventing these pre-cancerous lesions. The two-dose HPV vaccine is recommended for administration to It is recommended that girls ages 11-12 receive the two-dose HPV vaccine, and that those through age 26 receive the three-dose vaccination for “catch-up.”